CRS0540 Gram-positives
Preclinical program targeting antibiotic-resistant Gram-positive infections.
- MRSA skin infections
- MRSA & PRSP pneumonia
- Group A strep
- Group B strep and Listeria neonatal infections
- VRE bacteremia
- Anthrax
- Listeria food poisoning
Browse
Overview
Browse
Ongoing Studies
Browse
Presentations
Browse
News / Updates
CRS0540 Gram-positives Overview
We are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance. CRS0540 exhibits broad spectrum activity against all clinically significant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), Streptococcus pyogenes (Group A strep), Streptococcus agalactiae (Group B strep), vancomycin-resistant Enterococci (VRE), Bacillus anthracis (anthrax), and Listeria monocytogenes.
Key Areas of Study
- Novel mechanism of action based on inhibition of PolC, an essential DNA polymerase
- Oral bioavailability, facilitating outpatient treatment
- Bactericidal activity
- Low spontaneous resistance rates
- In vivo efficacy in preclinical models of infection
- Low propensity for toxicity observed in vitro and in vivo
Ongoing CRS0540 Gram-positives Studies
Novel antibacterial candidate CRS0540 is still in pre-clinical development, so no clinical studies are available for this drug candidate at the moment. Please check back soon for further updates.
CRS0540 Presentations
Presentation: World Antimicrobial Resistance (WAMR) Conference 2022
WAMR Conference 2022 Presentation Details Poster Presentation: Addressing the AMR Challenge:...
CRS0540 News / Updates
Publication of Data on the Novel Antibiotic CRS0540
Announcement Regarding CRS0540: Crestone, Inc. and Praedicare Inc. Announce the Publication of...
Become a Part of This Project
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor or a team member.
Inquiries
Have a question or comment? Follow the link below to contact us about general inquiries.
Careers
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Investors
If you're interested in becoming an investor to help fund our research and development, contact us today.